Antibiotic Trials for Coronary Heart Disease

Texas Heart Institute Journal

Volumn 31, Issue 1, 2004, Pages 33-38

  Anderson, Jeffrey L ^a   Muhlestein, Joseph B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic prophylaxis; Antibiotics, macrolide; Antibiotics therapeutic use; Arteriosclerosis etiology pathology prevention control; Azithromycin therapeutic use; Chlamydia infections; Chlamydia pneumoniae; Chronic disease; Inflammation

Indexed keywords

AMOXICILLIN; ATORVASTATIN; AZITHROMYCIN; CLARITHROMYCIN; GATIFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PRAVASTATIN; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SCREENING; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHESIS; INFLAMMATION; ISCHEMIC HEART DISEASE; MEDICAL INFORMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZATION; SECONDARY PREVENTION; SUPERINFECTION; TREATMENT INDICATION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 1642304871     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Anderson JL, Muhlestein JB. Acute coronary syndromes: the role of infection. In: Theroux P, editor. Acute coronary syndromes: a companion to Braunwald's heart disease. Philadelphia: Saunders; 2003. p. 88-107.
3. Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother 1989;33: 1634-5.
4. Schneider CA, Diedrichs H, Riedel KD, Zimmermann T, Hopp HW. In vivo uptake of azithromycin in human coronary plaques. Am J Cardiol 2000;86:789-91, A9.
5. Muhlestein JB, Anderson JL, Hammond EH, Zhao, L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
6. Fong IW. Value of animal models for Chlamydia pneumoniae-related atherosclerosis. Am Heart J 1999;138(5 Pt 2): S512-3.
7. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996;335:392-8.
8. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540-7.
9. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001;21:35-59.
10. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999;281:427-31.
11. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 2000;181 Suppl 3:S563-5.
12. Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis - the case for Chlamydia pneumoniae. Clin Cardiol 1997;20:829-36.
13. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
14. Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003;14:605-14.
15. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-7.
16. Dunne M. WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. Am Heart J 1999;138(5 Pt 2):S542-4.
17. Grayston JT. Secondary prevention antibiotic treatment trials for coronary artery disease. Circulation 2000;102:1742-3.
18. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003;361:809-13.
19. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003;290:1459-66.
20. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome, Circulation 2002;105:1555-60.
21. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357:2085-9.
22. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003; 107:1253-9.
23. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350:404-7.
24. Stone AF, Mendall M, Kaski JC, Gupta S, Camm J, Northfield T. Antibiotics against Chlamydia pneumoniae and Helicobacter pylori reduce further cardiovascular events in patients with acute coronary syndromes [abstract]. J Am Coll Cardiol 2001;37(2 Suppl A):349A.
25. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100:1369-73.
26. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-30.
27. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999; 84:595-8, A8.
28. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001;103:351-6.
29. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995;122:81-9.